AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7699487 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Depression Screen (SDS) for Depressive Disorders (MDD or Subsyndromal Depression - SubD)
Number of subjects: 221
Study 7699487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Rating Scale (HDRS) for MDD
Number of subjects: 221
Study 7699487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamilton Depression Rating Scale (HDRS) for SubD
Number of subjects: 221
Study 7699487 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional impairment in patients with MDD or SubD
Number of subjects: 221
Study 2713211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (1.25 mg)
Number of subjects: 8
Study 2713211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride (0.1 mg)
Number of subjects: 8
Study 2713211 — intervention group
Group type: EXPERIMENTAL
Intervention: Terguride (0.25 mg)
Number of subjects: 8
Study 2713211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 279253 — intervention group
Group type: EXPERIMENTAL
Intervention: Think-With Instructions
Number of subjects: 66
Study 279253 — intervention group
Group type: COMPARATOR
Intervention: trance induction
Number of subjects: 66
Study 279253 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 66
Study 30716716 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 75
Study 30716716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 27930609 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified delivery of pre-ART counseling sessions
Number of subjects: 0
Study 27930609 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 0
Study 27930609 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care CD4 testing
Number of subjects: 0
Study 27930609 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated ART initiation
Number of subjects: 0
Study 27930609 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncash financial incentives
Number of subjects: 0
Study 26022948 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline pleural irrigation (three times per day for 3 days)
Number of subjects: 35
Study 26022948 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 35
Study 26022948 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline pleural irrigation
Number of subjects: 35
Study 24111983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (40-160 mg/day)
Number of subjects: 283
Study 24111983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 24111983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (OLE phase)
Number of subjects: 283
Study 24111983 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone (RCT and OLE phases)
Number of subjects: 283
Study 24111983 — intervention group
Group type: COMPARATOR
Intervention: Ziprasidone and Placebo (RCT and OLE phases)
Number of subjects: 283
Study 21239571 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-contrast radiography
Number of subjects: 37
Study 21239571 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiography
Number of subjects: 37
Study 19725489 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 15772058 — intervention group
Group type: EXPERIMENTAL
Intervention: Power training (PWR; 4.73 rad/s)
Number of subjects: 17
Study 15772058 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (STR; 1.05 rad/s)
Number of subjects: 17
Study 15772058 — intervention group
Group type: COMPARATOR
Intervention: Both PWR and STR
Number of subjects: 17
Study 12470401 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose insulin with glucose, potassium and amino acids
Number of subjects: 25
Study 12470401 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 9867064 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (PE)
Number of subjects: 40
Study 9867064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7543114 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of GH (3.15 +/- 0.27 IU daily)
Number of subjects: 13
Study 7543114 — intervention group
Group type: COMPARATOR
Intervention: Daily subcutaneous injections of GH (3.15 +/- 0.27 IU daily)
Number of subjects: 13
Study 2565517 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed platelet concentrates (incubated at 37 degrees C for 1 hour)
Number of subjects: 15
Study 2565517 — intervention group
Group type: COMPARATOR
Intervention: Unwarmed platelet concentrates (stored at room temperature)
Number of subjects: 15
Study 330937 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg methylproscillaridin (MP)
Number of subjects: 14
Study 330937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 31642088 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application
Number of subjects: 360
Study 31642088 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet
Number of subjects: 360
Study 31642088 — intervention group
Group type: COMPARATOR
Intervention: Placebo booklet
Number of subjects: 360
Study 29706690 — intervention group
Group type: EXPERIMENTAL
Intervention: McGill stabilization exercises
Number of subjects: 34
Study 29706690 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 34
Study 28390207 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF dentifrices containing 2.5% or 5% small particle size CSPS (4 µm)
Number of subjects: 134
Study 28390207 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF or SMFP dentifrices containing 5% CSPS (14 µm)
Number of subjects: 134
Study 28390207 — intervention group
Group type: COMPARATOR
Intervention: Regular fluoride dentifrice
Number of subjects: 134
Study 25005784 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium citrate 150 mg twice daily
Number of subjects: 3000
Study 25005784 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 3000
Study 22799129 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (SRP) + ORN (test group)
Number of subjects: 58
Study 22799129 — intervention group
Group type: COMPARATOR
Intervention: Full-mouth scaling and root planing (SRP) + placebo (control group)
Number of subjects: 58
Study 20408344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (110 microg)
Number of subjects: 360
Study 20408344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (200 microg)
Number of subjects: 360
Study 20408344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Number of subjects: 360
Study 20408344 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate and fluticasone propionate
Number of subjects: 360
Study 18270828 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound
Number of subjects: 19
Study 15935263 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD triggers from personal environment
Number of subjects: 10
Study 15935263 — intervention group
Group type: EXPERIMENTAL
Intervention: Disorder-irrelevant disgusting and fear-inducing material
Number of subjects: 10
Study 15935263 — intervention group
Group type: EXPERIMENTAL
Intervention: Photos of individual OCD-triggers
Number of subjects: 10
Study 15935263 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversive picture conditions
Number of subjects: 10
Study 12028392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind map study technique
Number of subjects: 50
Study 12028392 — intervention group
Group type: COMPARATOR
Intervention: Self‐selected study technique
Number of subjects: 50
Study 9807075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 27
Study 9807075 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen with codeine
Number of subjects: 27
Study 8584148 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (6 micrograms/kg/min after a bolus dose of 60 micrograms/kg)
Number of subjects: 9
Study 8584148 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (0.6 microgram/kg/min after a bolus dose of 7 micrograms/kg)
Number of subjects: 9
Study 8584148 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 9
Study 2518868 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg cisapride q.d.s.
Number of subjects: 12
Study 2518868 — intervention group
Group type: COMPARATOR
Intervention: Placebo q.d.s.
Number of subjects: 12
Study 1180299 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy
Number of subjects: 119
Study 1180299 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 119
Study 31735500 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A alone (low dose Starter Group, n=6)
Number of subjects: 42
Study 31735500 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A (Group A, n=12)
Number of subjects: 42
Study 31735500 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A prime - MVA85A boost (Group B, n=12)
Number of subjects: 42
Study 31735500 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A - ChAdOx1 85A prime - MVA85A boost (Group C, n=12)
Number of subjects: 42
Study 31735500 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA85A
Number of subjects: 42
Study 30980618 — intervention group
Group type: EXPERIMENTAL
Intervention: cream containing herbal mixture
Number of subjects: 90
Study 30980618 — intervention group
Group type: COMPARATOR
Intervention: arbutin cream
Number of subjects: 90
Study 30980618 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 90
Study 27853882 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP infusion
Number of subjects: 48
Study 25885661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with peer mentors, specific milestones, and access to a physician informaticist.
Number of subjects: 30
Study 25885661 — intervention group
Group type: COMPARATOR
Intervention: Control group practices without support or guidance for registry implementation.
Number of subjects: 30
Study 23434214 — intervention group
Group type: COMPARATOR
Intervention: Standard Intervention
Number of subjects: 80
Study 23434214 — intervention group
Group type: COMPARATOR
Intervention: Insole
Number of subjects: 80
Study 23434214 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 80
Study 23434214 — intervention group
Group type: COMPARATOR
Intervention: Insole+Exercise
Number of subjects: 80
Study 21157850 — intervention group
Group type: EXPERIMENTAL
Intervention: Services by a mental health professional in primary care or specialty settings
Number of subjects: 792
Study 21157850 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 792
Study 20030859 — intervention group
Group type: EXPERIMENTAL
Intervention: Western and Chinese medicine together (Group B)
Number of subjects: 340
Study 20030859 — intervention group
Group type: COMPARATOR
Intervention: Western medicine only (Group A)
Number of subjects: 340
Study 17846293 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. low dose nesiritide (0.005 microg/Kg/min for 24 hours)
Number of subjects: 40
Study 17846293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15118189 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (vitamin E, 500 mg/d; vitamin C, 1 g/d; beta-carotene, 30 mg/d)
Number of subjects: 18
Study 15118189 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 18
Study 11697418 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg retinol equivalent (RE) with childhood immunization
Number of subjects: 467
Study 11697418 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg retinol equivalent (RE) with childhood immunization
Number of subjects: 467
Study 11697418 — intervention group
Group type: COMPARATOR
Intervention: Placebo with childhood immunization
Number of subjects: 467
Study 9730072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cornstarch-lubricated gloves
Number of subjects: 20
Study 9730072 — intervention group
Group type: EXPERIMENTAL
Intervention: Powder-free latex examination gloves
Number of subjects: 20
Study 9730072 — intervention group
Group type: COMPARATOR
Intervention: Powdered gloves
Number of subjects: 20
Study 8034780 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-tuft toothbrush
Number of subjects: 30
Study 8034780 — intervention group
Group type: COMPARATOR
Intervention: Vertical-tuft toothbrush
Number of subjects: 30
Study 30354969 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early and more frequent mobilization in addition to usual stroke unit care
Number of subjects: 2104
Study 30354969 — intervention group
Group type: COMPARATOR
Intervention: Usual stroke unit care
Number of subjects: 2104
Study 27422025 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic microfracture (MF)
Number of subjects: 114
Study 27422025 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic debridement (AD)
Number of subjects: 114
Study 27422025 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 114
Study 24984683 — intervention group
Group type: EXPERIMENTAL
Intervention: Low income
Number of subjects: 681
Study 24984683 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate income
Number of subjects: 681
Study 24984683 — intervention group
Group type: COMPARATOR
Intervention: Higher income
Number of subjects: 681
Study 22882543 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 µg twice a day, n = 30)
Number of subjects: 40
Study 22882543 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone (125 µg twice a day, n = 10)
Number of subjects: 40
Study 20729742 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated interferon‐α‐2a (180 μg/week) and ribavirin (1000‐1200 mg/day) for 48 weeks
Number of subjects: 575
Study 18554989 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 318
Study 18554989 — intervention group
Group type: EXPERIMENTAL
Intervention: Self management
Number of subjects: 318
Study 18554989 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 318
Study 18554989 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluation
Number of subjects: 318
Study 16869716 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate depletion
Number of subjects: 66
Study 16869716 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphate loading
Number of subjects: 66
Study 12540501 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of 4‐HPR/day for 5 years
Number of subjects: 1574
Study 12540501 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 1574
Study 10876750 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous irrigation with 40 micrograms/ml epirubicin solution for 20 hours after surgery
Number of subjects: 45
Study 10876750 — intervention group
Group type: COMPARATOR
Intervention: Continuous irrigation with saline
Number of subjects: 45
Study 10876750 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous irrigation with 40 micrograms/ml epirubicin solution for 20 hours after surgery (for solitary tumors)
Number of subjects: 45
Study 10876750 — intervention group
Group type: COMPARATOR
Intervention: Continuous irrigation with saline (for solitary tumors)
Number of subjects: 45
Study 9110838 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention (listening to music of their own choosing)
Number of subjects: 0
Study 8513773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyre pressure of 552 kPa
Number of subjects: 7
Study 8513773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyre pressure of 690 kPa
Number of subjects: 7
Study 8513773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyre pressure of 827 kPa
Number of subjects: 7
Study 8513773 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyre pressure of 965 kPa
Number of subjects: 7
Study 2942293 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangbao Solution
Number of subjects: 67
Study 2942293 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 31092278 — intervention group
Group type: EXPERIMENTAL
Intervention: Kilkari messages
Number of subjects: 5000
Study 31092278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Kilkari messages)
Number of subjects: 5000
Study 29734740 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Regulation Focused CBT (MR‐CBT)
Number of subjects: 27
Study 29734740 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 27
Study 26956843 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Number of subjects: 137
Study 26956843 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 137
Study 25416400 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target (T2T) approach
Number of subjects: 530
Study 25416400 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 530
Study 22127619 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL instructions
Number of subjects: 94
Study 22127619 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL + Graphic
Number of subjects: 94
Study 22127619 — intervention group
Group type: COMPARATOR
Intervention: Standard prescription instructions (usual care)
Number of subjects: 94
Study 20622409 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokeless tobacco users
Number of subjects: 1200
Study 20622409 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco users
Number of subjects: 1200
Study 18194120 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (steroid-free regimen): tacrolimus, mycophenolate mofetil, basiliximab induction, and steroids only for 3 days
Number of subjects: 100
Study 18194120 — intervention group
Group type: COMPARATOR
Intervention: Control group (steroid maintenance): tacrolimus, mycophenolate mofetil, basiliximab induction, and steroid maintenance
Number of subjects: 100
Study 16055644 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation before reading health-risk information
Number of subjects: 0
Study 16055644 — intervention group
Group type: COMPARATOR
Intervention: Non-affirmed group (control)
Number of subjects: 0
Study 12133094 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate (OTF) 2.5 ml (15‐20 microg.kg(‐1))
Number of subjects: 80
Study 12133094 — intervention group
Group type: COMPARATOR
Intervention: Midazolam syrup (0.5 mg.kg(‐1))
Number of subjects: 80
Study 10435771 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 30
Study 10435771 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 30
Study 7549900 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 198
Study 7549900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 2181941 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol I (5-FU 270-300 mg/m2 iv from day 1 to day 5 and ADM 25 mg/m2 iv on day 5)
Number of subjects: 77
Study 2181941 — intervention group
Group type: COMPARATOR
Intervention: Protocol II (5-FU, ADM plus CDDP 70 mg/m2 iv on day 1)
Number of subjects: 77
Study 2181941 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 77
Study 7233072 — intervention group
Group type: EXPERIMENTAL
Intervention: 3:1 jejunoileal ratio
Number of subjects: 265
Study 7233072 — intervention group
Group type: EXPERIMENTAL
Intervention: 1:3 jejunoileal ratio
Number of subjects: 265
Study 7233072 — intervention group
Group type: COMPARATOR
Intervention: Unoperated patients
Number of subjects: 265
Study 31831059 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 28150508 — intervention group
Group type: EXPERIMENTAL
Intervention: CF guided PVAI
Number of subjects: 50
Study 28150508 — intervention group
Group type: COMPARATOR
Intervention: Conventional PVAI
Number of subjects: 50
Study 26228714 — intervention group
Group type: EXPERIMENTAL
Intervention: Bench step exercise (3 times per day, 10-20 min each session, ≥140 min/week for 12 weeks)
Number of subjects: 62
Study 26228714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 62
Study 23588946 — intervention group
Group type: EXPERIMENTAL
Intervention: IV abatacept
Number of subjects: 3173
Study 21423253 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation cycling (FESC)
Number of subjects: 30
Study 21423253 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive cycling (PC)
Number of subjects: 30
Study 21423253 — intervention group
Group type: COMPARATOR
Intervention: Non-cycling, electrically stimulated exercise (ES)
Number of subjects: 30
Study 19517893 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product (Omep-20)
Number of subjects: 24
Study 19517893 — intervention group
Group type: COMPARATOR
Intervention: Reference product
Number of subjects: 24
Study 17672185 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous autotransfusion system (group B)
Number of subjects: 30
Study 17672185 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 30
Study 15145465 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondeficit patients
Number of subjects: 61
Study 15145465 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficit syndrome patients
Number of subjects: 61
Study 15145465 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 61
Study 15145465 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 61
Study 11255587 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-delivered brief smoking cessation intervention
Number of subjects: 1120
Study 11255587 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1120
Study 9031450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) 150 anti‐Xa units per kg body weight, administered subcutaneously every 12 h for 7 days, initiated prior to streptokinase (SK)
Number of subjects: 100